BTCC / BTCC Square / Global Cryptocurrency /
Novartis AG Reports Strong Q2 Growth Fueled by Oncology Portfolio

Novartis AG Reports Strong Q2 Growth Fueled by Oncology Portfolio

Global Cryptocurrency
Release Time:
2025-07-18 17:07:02
0
BTCCSquare news:

Novartis AG delivered a robust Q2 performance, with Core EPS surging 24% to $2.42, exceeding analyst expectations. The pharmaceutical giant posted 11% constant-currency sales growth, powered by its oncology franchise including Kisqali (+64% globally) and Pluvicto, while facing headwinds in Cosentyx performance.

Operating margins expanded 340 basis points to 42.2%, demonstrating disciplined cost management. The company announced a $10 billion share repurchase program through 2027, signaling confidence in its financial position despite a 3.25% stock decline post-earnings.

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users